Evidence map›Paper›PMID 28132018›Full record

ArticleJournal of the National Cancer Institute2017

Proportion of Never-Smoker Non-Small Cell Lung Cancer Patients at Three Diverse Institutions.

Lorraine Pelosof, Chul Ahn, Ang Gao, Leora Horn, Alejandra Madrigales, Joan Cox, Dauphne McGavic, John D Minna, Adi F Gazdar, Joan Schiller

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in Journal of the National Cancer Institute, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07126626 (Multi-center Prospective Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer), which is not on this map. Cited by 93 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07126626 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Multi-center Prospective Validation of the SPOT-MAS Lung Test Using Circulating Tumor DNA for the Detection of Lung Cancer

TypeobservationalSponsorGene SolutionsRan2025 to 2027Enrolled1,184ConditionsLung Diseases, Lung Cancer Screening
3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Over- and underscreening for lung cancer.Translational lung cancer research · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Rethinking the microenvironment's role in chemical-induced malignancy.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Lorraine PelosofAffiliations of authors: Department of Internal Medicine, Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center (LP, AM, JDM, JS), Department of Biostatistics (CA, AG), Hamon Center for Therapeutic Oncology Research (JDM, AFG), Department of Pharmacology (JDM), Department of Pathology (AFG), UT Southwestern, Dallas, TX; Department of Hematology/Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN (LH, DM); Parkland Memorial Hospital, Dallas, TX (JC).
Chul AhnAffiliations of authors: Department of Internal Medicine, Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center (LP, AM, JDM, JS), Department of Biostatistics (CA, AG), Hamon Center for Therapeutic Oncology Research (JDM, AFG), Department of Pharmacology (JDM), Department of Pathology (AFG), UT Southwestern, Dallas, TX; Department of Hematology/Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN (LH, DM); Parkland Memorial Hospital, Dallas, TX (JC).
Ang GaoAffiliations of authors: Department of Internal Medicine, Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center (LP, AM, JDM, JS), Department of Biostatistics (CA, AG), Hamon Center for Therapeutic Oncology Research (JDM, AFG), Department of Pharmacology (JDM), Department of Pathology (AFG), UT Southwestern, Dallas, TX; Department of Hematology/Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN (LH, DM); Parkland Memorial Hospital, Dallas, TX (JC).
Leora HornAffiliations of authors: Department of Internal Medicine, Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center (LP, AM, JDM, JS), Department of Biostatistics (CA, AG), Hamon Center for Therapeutic Oncology Research (JDM, AFG), Department of Pharmacology (JDM), Department of Pathology (AFG), UT Southwestern, Dallas, TX; Department of Hematology/Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN (LH, DM); Parkland Memorial Hospital, Dallas, TX (JC).
Alejandra MadrigalesAffiliations of authors: Department of Internal Medicine, Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center (LP, AM, JDM, JS), Department of Biostatistics (CA, AG), Hamon Center for Therapeutic Oncology Research (JDM, AFG), Department of Pharmacology (JDM), Department of Pathology (AFG), UT Southwestern, Dallas, TX; Department of Hematology/Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN (LH, DM); Parkland Memorial Hospital, Dallas, TX (JC).
Joan CoxAffiliations of authors: Department of Internal Medicine, Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center (LP, AM, JDM, JS), Department of Biostatistics (CA, AG), Hamon Center for Therapeutic Oncology Research (JDM, AFG), Department of Pharmacology (JDM), Department of Pathology (AFG), UT Southwestern, Dallas, TX; Department of Hematology/Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN (LH, DM); Parkland Memorial Hospital, Dallas, TX (JC).
Dauphne McGavicAffiliations of authors: Department of Internal Medicine, Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center (LP, AM, JDM, JS), Department of Biostatistics (CA, AG), Hamon Center for Therapeutic Oncology Research (JDM, AFG), Department of Pharmacology (JDM), Department of Pathology (AFG), UT Southwestern, Dallas, TX; Department of Hematology/Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN (LH, DM); Parkland Memorial Hospital, Dallas, TX (JC).
John D MinnaAffiliations of authors: Department of Internal Medicine, Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center (LP, AM, JDM, JS), Department of Biostatistics (CA, AG), Hamon Center for Therapeutic Oncology Research (JDM, AFG), Department of Pharmacology (JDM), Department of Pathology (AFG), UT Southwestern, Dallas, TX; Department of Hematology/Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN (LH, DM); Parkland Memorial Hospital, Dallas, TX (JC).
Adi F GazdarAffiliations of authors: Department of Internal Medicine, Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center (LP, AM, JDM, JS), Department of Biostatistics (CA, AG), Hamon Center for Therapeutic Oncology Research (JDM, AFG), Department of Pharmacology (JDM), Department of Pathology (AFG), UT Southwestern, Dallas, TX; Department of Hematology/Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN (LH, DM); Parkland Memorial Hospital, Dallas, TX (JC).
Joan SchillerAffiliations of authors: Department of Internal Medicine, Hematology/Oncology, Harold C. Simmons Comprehensive Cancer Center (LP, AM, JDM, JS), Department of Biostatistics (CA, AG), Hamon Center for Therapeutic Oncology Research (JDM, AFG), Department of Pharmacology (JDM), Department of Pathology (AFG), UT Southwestern, Dallas, TX; Department of Hematology/Oncology, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Nashville, TN (LH, DM); Parkland Memorial Hospital, Dallas, TX (JC).

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI GIBBONS, DON LYNN · 1996 to 2024
$57.4M
NCI NIH HHS P50 CA070907
6 · The paper itself

Abstract

Background: Approximately 10% to 15% of lung cancer cases in the United States occur in never smokers, but there has been much debate about whether this rate is increasing. To determine whether the proportion of never smokers among lung cancer cases is increasing, we conducted a retrospective study using registries from The University of Texas Southwestern Medical Center, Parkland Hospital, and Vanderbilt University. Methods: Registries were queried for demographic information from 1990 to 2013 including sex, age, stage, and self-reported smoking history. Ten thousand five hundred ninety-three non-small cell lung cancer (NSCLC) case patients and 1510 small cell lung cancer (SCLC) case patients were captured, and logistic regression analysis was performed. All statistical tests were two-sided. Results: The proportion of never-smoker NSCLC patients increased from 8.0% in the years 1990 to 1995 to 14.9% in 2011 to 2013 (P < .001). This increase was also observed using multivariable logistic regression after controlling for sex, stage at diagnosis, and race/ethnicity. The percentage of never smokers among SCLC case patients (1.5% in 1990-1995 to 2.5% in 2011-2013, P = .36) or squamous cell NSCLC case patients did not statistically significantly change during this period. Conclusions: This study demonstrates an increasing proportion of NSCLC patients who have never smoked in a large, diverse patient population between 1990 and 2013. Given that this increase appears independent of sex, stage, and race/ethnicity and also occurred in our county hospital, this trend is unlikely due to changes in referral patterns and suggests that the actual incidence of lung cancer in never smokers is increasing.

Indexed as

AgedCarcinoma, Non-Small-Cell LungFemaleHumansIncidenceLogistic ModelsLung NeoplasmsMaleMiddle AgedMultivariate AnalysisRegistriesRetrospective StudiesSmokingTennesseeTexas

Identifiers

PMID28132018
PMCPMC6279285

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.